How does an option-and-license collaboration actually work, and who controls the resulting antibody IP? AbCellera Biologics Inc. (Nasdaq: ABCL) answered that question in concrete terms on June 17, 2026, when it filed a Form 8-K under Item 8.01 disclosing a preclinical research collaboration, option and license agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ). The headline number is large — up to $792 million per program — but the more instructive detail is the deal’s architecture: a staged option structure that keeps Jazz’s committed cash modest and pushes the bulk of AbCellera’s potential value into milestones that may never be paid. For an IP-focused reader, the question is not the topline; it is what gets licensed, when, and on whose terms.
The subject matter is T-cell engaging (TCE) multispecific antibodies — biologics that physically bridge a patient’s cytotoxic T cells to a tumor cell, forcing the immune system to attack a cancer it might otherwise ignore. The collaboration targets multiple gastrointestinal (GI) cancers and other solid tumors, a notoriously hard arena for the modality because solid tumors lack the clean, abundant surface targets that made TCEs successful in blood cancers. AbCellera’s contribution is its discovery engine: per the press release attached as Exhibit 99.1, its TCE platform is “a fully integrated capability, from discovery to clinical manufacturing,” and includes “novel and proprietary panels of CD3-binding antibodies, costimulatory targeting arms, multispecific protein engineering technology, and a suite of high-throughput functional assays.” Those CD3-binding panels and engineering tools are the platform IP AbCellera retains and brings to bear — the asset that lets it run discovery for partner after partner without licensing away the underlying engine.
Who controls the IP, and when does Jazz actually license it?
This is where the option-and-license label does real work, and where the document is precise. The collaboration is not a sale of antibodies; it is a sequenced grant of rights contingent on Jazz electing to proceed and paying to do so.
"Jazz is granted an option in connection with each research program and, following exercise of its option and payment of an option fee, will have the exclusive, worldwide right to develop and commercialize each program."— AbCellera Biologics Inc. Form 8-K, Exhibit 99.1, source
Read carefully, that sentence sets the control logic for the entire deal. AbCellera performs the discovery and early-stage research; the exclusive, worldwide development-and-commercialization right does not transfer to Jazz automatically. It transfers only on a two-part trigger — option exercise plus an option fee — and it transfers per program, not as a portfolio. That granularity matters for an IP analysis: Jazz can take one program forward and let another lapse, meaning the candidates AbCellera generates do not all end up under Jazz’s control. Anything Jazz declines stays with AbCellera, and the underlying platform technology never moves at all. This is the structural opposite of a buyout; it is a series of independently exercisable, fee-gated licenses layered on top of a retained discovery engine.
The transaction terms, separated from the topline
The filing’s “Transaction Terms” section is where the staged economics become legible. AbCellera will perform discovery and early-stage research for two initial programs, with a commitment to start a third discovery program within 12 months. For the first two research programs AbCellera receives $56 million in total upfront payments, with an additional $28 million due upon initiation of the third program — bringing guaranteed-on-initiation cash to roughly $84 million across the three near-term programs. Everything beyond that is contingent.
The much-quoted $792 million figure is explicitly framed as a per-program ceiling that depends on Jazz exercising its option: should Jazz exercise for development, AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments, along with tiered royalties on net sales ranging from mid-single digits to low double-digits. In deal-desk terms, the $56 million is real, signed cash; the $792 million is “biobucks” — a stack of milestones that only fully materializes if a program clears discovery, survives the option decision, advances through development and regulatory review, and reaches meaningful commercial sales. The royalty range — mid-single digits to low double-digits on net sales — is the tail that pays out only on an approved, selling product, and it sits on Jazz’s commercial revenue rather than AbCellera’s. The deal can also expand: Jazz and AbCellera may mutually agree to initiate up to two additional programs, and AbCellera may conduct IND-enabling studies and manufacture clinical supply for any program — optional scope that converts the discovery partner into a potential manufacturing partner if both sides agree.
Why the structure favors the partner’s optionality
The architecture here is a textbook example of how a platform company monetizes a discovery engine without surrendering it, and of how a partner buys cheap optionality on hard biology. Jazz’s committed downside is the upfront and the option fees; if a GI-cancer TCE program fails to produce a candidate worth advancing, Jazz simply does not exercise, and its exposure is capped near the upfront. AbCellera, in turn, keeps its CD3-binding panels, costimulatory arms, and protein-engineering technology — the same engine it can redeploy for the next collaboration — while booking near-term research revenue and a contingent claim on far larger milestone and royalty streams.
For an IP reader the distinctions to hold onto are these: control of each candidate’s development and commercialization rights is gated, exclusive, worldwide, and per-program, vesting only on option exercise and fee payment; the platform technology is retained, not licensed; and the eligible economics are dominated by contingent milestones, not signed cash. The press release’s own framing — that Jazz “has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration” — should be read as describing a right Jazz may choose to exercise program by program, not a transfer that has already occurred. None of the candidates exist yet; this is a preclinical research collaboration whose entire value chain runs from discovery through an option gate to potential clinical development.
The full terms, the platform description, and the per-program economics are set out in AbCellera’s Form 8-K and the attached Exhibit 99.1 press release, filed with the SEC under accession number 0001703057-26-000035. As always with collaboration 8-Ks, the press release is the announced framing; the operative rights and obligations live in the definitive agreement, and what the 8-K confirms is the staged, option-gated shape of the deal rather than any single program’s certainty.